IL199350A - Pneumococcal polysaccharide-protein conjugate composition - Google Patents

Pneumococcal polysaccharide-protein conjugate composition

Info

Publication number
IL199350A
IL199350A IL199350A IL19935009A IL199350A IL 199350 A IL199350 A IL 199350A IL 199350 A IL199350 A IL 199350A IL 19935009 A IL19935009 A IL 19935009A IL 199350 A IL199350 A IL 199350A
Authority
IL
Israel
Prior art keywords
polysaccharide
streptococcus pneumoniae
immunogenic composition
carrier protein
protein conjugate
Prior art date
Application number
IL199350A
Other languages
Hebrew (he)
Other versions
IL199350A0 (en
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39876611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL199350(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of IL199350A0 publication Critical patent/IL199350A0/en
Publication of IL199350A publication Critical patent/IL199350A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dry Formation Of Fiberboard And The Like (AREA)

Abstract

An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Also described is a method for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 3 polysaccharide covalently linked to a carrier protein, the method including periodic acid oxidation of the polysaccharide in the presence of bivalent cations.
IL199350A 2006-12-22 2009-06-15 Pneumococcal polysaccharide-protein conjugate composition IL199350A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/644,924 US7709001B2 (en) 2005-04-08 2006-12-22 Multivalent pneumococcal polysaccharide-protein conjugate composition
PCT/US2007/086941 WO2008143709A2 (en) 2006-12-22 2007-12-10 Multivalent pneumococcal polysaccharide-protein conjugate composition

Publications (2)

Publication Number Publication Date
IL199350A0 IL199350A0 (en) 2010-03-28
IL199350A true IL199350A (en) 2013-05-30

Family

ID=39876611

Family Applications (2)

Application Number Title Priority Date Filing Date
IL199350A IL199350A (en) 2006-12-22 2009-06-15 Pneumococcal polysaccharide-protein conjugate composition
IL222793A IL222793A (en) 2006-12-22 2012-11-01 Multivalent pneumococcal polysaccharide-protein conjugate composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL222793A IL222793A (en) 2006-12-22 2012-11-01 Multivalent pneumococcal polysaccharide-protein conjugate composition

Country Status (21)

Country Link
US (2) US7709001B2 (en)
EP (2) EP2094298B1 (en)
JP (1) JP5523836B2 (en)
KR (3) KR101700837B1 (en)
CN (2) CN103599529B (en)
AT (1) ATE545431T1 (en)
AU (1) AU2007353769B2 (en)
BR (1) BRPI0720624A2 (en)
CA (1) CA2673477C (en)
CL (2) CL2007003782A1 (en)
DK (2) DK2094298T3 (en)
ES (2) ES2424940T3 (en)
HK (1) HK1191567A1 (en)
IL (2) IL199350A (en)
MX (1) MX2009006705A (en)
PL (2) PL2417983T3 (en)
PT (2) PT2094298E (en)
RU (1) RU2493870C2 (en)
SI (2) SI2417983T1 (en)
WO (1) WO2008143709A2 (en)
ZA (1) ZA200904760B (en)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
IL308456A (en) * 2005-04-08 2024-01-01 Wyeth Llc Multivalent pneumococcal polysacharide-protein conjugate composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20070253985A1 (en) * 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP2436700B8 (en) 2007-03-23 2018-08-01 Wyeth LLC Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
JP2011525477A (en) * 2008-03-04 2011-09-22 リクイディア・テクノロジーズ・インコーポレーテッド Immunomodulator particles and method of treatment
CN103816870B (en) 2008-12-03 2016-11-23 株式会社钟化 Porous carrier containing formoxyl, the adsorbate using this porous carrier and their manufacture method
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2385981B1 (en) 2008-12-18 2019-09-04 Wyeth LLC Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon
MX2011006432A (en) * 2008-12-18 2011-09-29 Wyeth Llc Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight.
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
US9649372B2 (en) 2009-12-22 2017-05-16 Sanofi Pasteur Limited Immunogenic compositions and related methods
US20130209564A1 (en) * 2010-02-22 2013-08-15 Shyam M. Rele Polysaccharide Particle Vaccines
CN101785857B (en) * 2010-03-05 2012-09-26 成都安特金生物技术有限公司 Novel pneumococcal conjugate vaccine and preparation method thereof
CN107080839A (en) 2010-05-26 2017-08-22 西莱克塔生物科技公司 The synthesis nano-carrier vaccine of multivalence
EP2575870B1 (en) 2010-06-04 2016-12-07 Wyeth LLC Vaccine formulations
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
CN102462839B (en) * 2010-11-12 2016-03-30 北京生物制品研究所 polysaccharide conjugate vaccine and preparation method thereof
JP6191082B2 (en) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Combination vaccine with lower dose of antigen and / or adjuvant
CN103702687A (en) 2011-07-29 2014-04-02 西莱克塔生物科技公司 Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
KR101315599B1 (en) 2011-10-25 2013-10-10 건국대학교 산학협력단 Glycoprotein conjugate of cps14 and horseradish peroxidase
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
KR102057217B1 (en) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2013311702A1 (en) 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
ES2651415T3 (en) * 2012-09-07 2018-01-26 Sk Chemicals Co., Ltd. Production method of a capsular polysaccharide that has a pneumococcal serotype
KR20140075196A (en) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
BR112015014250A2 (en) 2012-12-18 2017-07-11 Glaxosmithkline Biologicals Sa method to immunize a baby, combination vaccine and kit
EP4169929A1 (en) 2012-12-20 2023-04-26 Pfizer Inc. Immunogenic compositions comprising pn-serotype 12f
US9782468B2 (en) * 2013-05-20 2017-10-10 Shantha Biotechnics Private Limited Purification of polysaccharide protein conjugates
WO2015073831A1 (en) * 2013-11-15 2015-05-21 Liquidia Technologies, Inc. Virtual conjugate particles
IL296681B2 (en) * 2014-01-21 2024-09-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HUE055553T2 (en) 2014-01-21 2021-12-28 Pfizer Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3957321A3 (en) 2014-01-21 2022-07-13 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
CN104069504B (en) * 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 A method of enhancing polysaccharide protein conjugate immunogenicity
EP2987408A1 (en) * 2014-08-20 2016-02-24 National University of Ireland, Galway Iodophor composition with improved stability in the presence of organic material
CN107427568B (en) 2015-01-15 2021-12-14 辉瑞公司 Immunogenic compositions for use in pneumococcal vaccines
PE20180172A1 (en) 2015-05-04 2018-01-22 Pfizer PROTEIN-POLYSACCHARIDE CONJUGATES OF STREPTOCOCUS GROUP B, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS INCLUDING CONJUGATES AND THEIR USES
US11147863B2 (en) * 2015-06-23 2021-10-19 Biological E Limited Multivalent pneumococcal conjugate vaccine
CN106109486A (en) * 2015-07-06 2016-11-16 北京科兴中维生物技术有限公司 A kind of compositions and preparation method and application
PE20240927A1 (en) 2015-07-21 2024-04-30 Pfizer IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS THAT COMPRISE THEM AND THEIR USES
CN108289944A (en) * 2015-10-07 2018-07-17 勃林格殷格翰动物保健公司 Multivalence Streptococcus suis polysaccharide-protein conjugate composition
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11058757B2 (en) 2016-03-31 2021-07-13 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
JP7001687B2 (en) 2016-08-05 2022-02-04 サノフィ パスツール インコーポレイティッド Polyvalent pneumococcal polysaccharide-protein conjugate composition
JP7001686B2 (en) 2016-08-05 2022-02-04 サノフィ パスツール インコーポレイティッド Polyvalent pneumococcal polysaccharide-protein conjugate composition
CU24660B1 (en) 2016-09-30 2023-05-11 Biological E Ltd MULTIVALENT VACCINE COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES USING PSAA AND CRM197 CARRIER PROTEINS
WO2018080213A1 (en) * 2016-10-28 2018-05-03 주식회사 엘지화학 Multivalent immunogenic composition having increased igg titer, and use thereof
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
KR20190103256A (en) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 Polypeptide-antigen conjugates with unnatural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
PL3570879T3 (en) 2017-01-20 2022-06-20 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11197921B2 (en) * 2017-01-31 2021-12-14 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
US11246918B2 (en) 2017-02-03 2022-02-15 Eva Barbara Schadeck Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
US11400162B2 (en) * 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
EP3589314A4 (en) * 2017-02-24 2021-04-21 Merck Sharp & Dohme Corp. Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
EP3634481A4 (en) * 2017-06-10 2021-07-21 Inventprise, LLC. Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
WO2019043245A1 (en) * 2017-09-04 2019-03-07 London School Of Hygiene And Tropical Medicine Microbial cells expressing streptococcal serotypes
FI3678654T3 (en) 2017-09-07 2024-09-02 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CA3074703A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
AU2018328040A1 (en) * 2017-09-07 2020-03-19 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
WO2019050816A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN117982633A (en) 2017-12-06 2024-05-07 默沙东有限责任公司 Compositions comprising Streptococcus pneumoniae polysaccharide protein conjugates and methods of use thereof
SG11202006388SA (en) * 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
SG11202006387QA (en) * 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
US11951162B2 (en) 2018-04-18 2024-04-09 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
EP3787673A4 (en) * 2018-04-30 2022-04-27 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
WO2019212844A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
JP7399934B2 (en) 2018-07-04 2023-12-18 バックスサイト・インコーポレイテッド Improvement of immunogenic complexes
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EA202191638A1 (en) 2018-10-12 2021-12-27 Байолоджикал И Лимитед MULTIVALENT VACCINE BASED ON PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
SG11202106541WA (en) 2018-12-19 2021-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP4003410A1 (en) 2019-07-31 2022-06-01 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
WO2021084429A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021165928A2 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2023537945A (en) 2020-08-10 2023-09-06 インベントプライズ・インコーポレイテッド Multivalent pneumococcal glycoconjugate vaccine containing emerging serotype 24F
EP4203995A1 (en) 2020-08-26 2023-07-05 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
AU2021368151B2 (en) 2020-10-27 2024-09-05 Pfizer Inc. Escherichia coli compositions and methods thereof
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
JP2023549736A (en) 2020-11-10 2023-11-29 ファイザー・インク Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
EP4333879A1 (en) 2021-05-03 2024-03-13 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4346892A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL314243A (en) 2022-01-13 2024-09-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3926258A (en) * 1972-12-27 1975-12-16 Phillips Petroleum Co Method for reducing formation permeability with gelled polymer solution having delayed gel time
US4097666A (en) * 1976-04-29 1978-06-27 The Institute Of Paper Chemistry Solvent system for polysaccharides
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US5110908A (en) 1986-12-31 1992-05-05 Praxis Biologics, Inc. Haemophilus influenzae peptides and proteins
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
KR100188323B1 (en) 1989-03-09 1999-06-01 이곤 이이 버어그 Vaccines for nontypable haemophilus influenzae
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
WO1993013302A1 (en) 1991-12-23 1993-07-08 Michael Zoche Engine with oil separator
JPH0698749A (en) * 1992-09-21 1994-04-12 Sapporo Breweries Ltd Production of beer having high fermentation degree
EP0616034B1 (en) 1993-03-05 2004-10-20 Wyeth Holdings Corporation Plasmid for production of CRM protein and diphtheria toxin
US5712118A (en) 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5770213A (en) 1994-05-05 1998-06-23 American Cyanamid Company Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection
US5607846A (en) 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5643725A (en) 1994-07-19 1997-07-01 American Cyanamid Company Sequence and analysis of LKP pilin structural genes and the LKP pili operon of nontypable haemophilus influenzae
US6676948B2 (en) 1994-08-25 2004-01-13 Washington University Haemophilus adherence and penetration proteins
US6245337B1 (en) 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
DE4432899A1 (en) * 1994-09-15 1996-03-21 Wacker Chemie Gmbh Crosslinkable polymer powder compositions
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US6221365B1 (en) 1996-07-26 2001-04-24 American Cyanamid Company NucA protein of Haemophilus influenzae
EP0948625B1 (en) 1996-12-20 2011-01-26 The Board Of Regents, The University Of Texas System Uspa1 and uspa2 antigens of moraxella catarrhalis
DK1005487T3 (en) 1997-01-31 2006-11-13 Wyeth Corp Outer 74 kD membrane protein from Moraxella catarrhalis
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (en) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc MULTIVALENT VACCINE COMPOSITION WITH MIXED CARRIER
DK1037642T3 (en) * 1997-12-09 2009-07-06 Biomed Frontiers Inc Modified polysaccharides with altered biological recognition
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
EP1115875A1 (en) 1998-09-24 2001-07-18 Regents Of The University Of Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
AU770333B2 (en) 1998-09-30 2004-02-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mutant cholera holotoxin as an adjuvant
EP1034792A1 (en) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
WO2000056360A2 (en) * 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against antigens from bacteriae
KR100283848B1 (en) * 1999-03-19 2001-02-15 서경배 A method for preparation of stabilized enzymes or proteins and compositions for external application containing stabilized enzymes or proteins prepared thereby
AU782566B2 (en) 1999-06-25 2005-08-11 Wyeth Holdings Corporation Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria
CN101586143A (en) * 2000-03-16 2009-11-25 费城儿童医院 Modulating production of pneumococcal capsular polysaccharide
GB0011108D0 (en) 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0012079D0 (en) 2000-05-18 2000-07-12 Microscience Ltd Virulence gene and protein, and their use
EP1946769B1 (en) * 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
GB0020952D0 (en) 2000-08-24 2000-10-11 Microscience Ltd Genes and proteins and their uses
ATE267767T1 (en) * 2000-12-13 2004-06-15 Sca Hygiene Prod Zeist Bv RECOVERY PROCESS FOR USED PERIODATE
EP1355918B9 (en) 2000-12-28 2012-01-25 Wyeth LLC Recombinant protective protein from $i(streptococcus pneumoniae)
EP2261241A1 (en) 2001-04-16 2010-12-15 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
JP2004535187A (en) 2001-06-07 2004-11-25 ワイス・ホールデイングス・コーポレーシヨン Mutant forms of cholera holotoxin as adjuvants
KR100877258B1 (en) 2001-06-07 2009-01-12 와이어쓰 홀딩스 코포레이션 Mutant forms of cholera holotoxin as an adjuvant
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
AU2002363925A1 (en) 2001-11-29 2003-06-17 Wyeth Holdings Corporation ALLOIOCOCCUS OTITIDIS OPEN READING FRAMES (ORFs) ENCODING POLYPEPTIDE ANTIGENS, IMMUNOGENIC COMPOSITIONS AND USES THEREOF
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
BR0308441A (en) 2002-03-15 2005-01-18 Wyeth Corp Non-typeable haemophilus influenzae p4 variant protein, immunogenic composition, isolated nucleotide molecule, host cell, and methods for inducing an immune response in a human against h. non-typifiable influenzae, and to produce a variant protein of p4
AU2002309259A1 (en) * 2002-05-09 2003-11-11 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
WO2004011027A1 (en) 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
US20060121058A1 (en) * 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
EP1549135A4 (en) * 2002-09-20 2006-01-11 Us Agriculture Vaccine compositions and adjuvant
FR2850106B1 (en) 2003-01-17 2005-02-25 Aventis Pasteur CONJUGATES OBTAINED BY REDUCTIVE AMINATION OF THE CAPSULAR POLYSACCHARIDE OF THE SEROTYPE PNEUMOCOCCUS 5
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
WO2004094596A2 (en) 2003-04-16 2004-11-04 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
CN1241937C (en) * 2003-07-04 2006-02-15 上海健益科技发展有限公司 Polyvalent pneumococcal polysaccharide combination vaccine
BRPI0413309B8 (en) * 2003-08-06 2021-05-25 The Government Of The Us Secretary Department Of Health And Human Services method for preparing a polysaccharide-protein conjugate vaccine
SI1664319T1 (en) * 2003-09-11 2010-06-30 An Vws De Staat Der Nederlande Process for producing a capsular polysaccharide for use in conjugate vaccines
FR2857364B1 (en) 2003-12-08 2005-09-23 Aventis Pasteur DOSAGE OF TECHIC ACIDS OF BACTERIA GRAM +
EA012984B1 (en) 2003-12-17 2010-02-26 Вайет Immunogenic peptide carrier conjugates and method of producing same
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc Multivalent pneumococcal polysacharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition

Also Published As

Publication number Publication date
AU2007353769B2 (en) 2013-01-10
US7709001B2 (en) 2010-05-04
MX2009006705A (en) 2009-06-30
AU2007353769A1 (en) 2008-11-27
KR20150140411A (en) 2015-12-15
CN103599529B (en) 2016-03-16
WO2008143709A3 (en) 2009-01-08
US8603484B2 (en) 2013-12-10
WO2008143709A2 (en) 2008-11-27
KR101511392B1 (en) 2015-04-13
PL2417983T3 (en) 2013-10-31
US20070231340A1 (en) 2007-10-04
PT2417983E (en) 2013-08-26
HK1191567A1 (en) 2014-08-01
CN101610785A (en) 2009-12-23
EP2417983A1 (en) 2012-02-15
ES2379834T3 (en) 2012-05-04
IL222793A0 (en) 2012-12-31
JP5523836B2 (en) 2014-06-18
EP2094298A2 (en) 2009-09-02
IL199350A0 (en) 2010-03-28
DK2417983T3 (en) 2013-08-26
RU2009125216A (en) 2011-01-27
SI2094298T1 (en) 2012-04-30
JP2010513549A (en) 2010-04-30
SI2417983T1 (en) 2013-09-30
US20100316666A1 (en) 2010-12-16
EP2417983B1 (en) 2013-06-26
CL2007003782A1 (en) 2009-01-16
KR101700837B1 (en) 2017-02-01
KR20090096731A (en) 2009-09-14
KR20140130567A (en) 2014-11-10
BRPI0720624A2 (en) 2014-03-25
CN101610785B (en) 2013-11-27
DK2094298T3 (en) 2012-03-26
ATE545431T1 (en) 2012-03-15
IL222793A (en) 2015-08-31
ES2424940T3 (en) 2013-10-10
EP2094298B1 (en) 2012-02-15
CL2017001842A1 (en) 2018-05-04
CA2673477A1 (en) 2008-11-27
CA2673477C (en) 2013-09-10
RU2493870C2 (en) 2013-09-27
PL2094298T3 (en) 2012-06-29
PT2094298E (en) 2012-04-03
CN103599529A (en) 2014-02-26
ZA200904760B (en) 2010-04-28

Similar Documents

Publication Publication Date Title
HK1191567A1 (en) Multivalent pneumococcal polysaccharide protein conjugate composition
IL186367A (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
MX336934B (en) Multivalent pneumococcal polysaccharide-protein conjugate composition.
WO2008079732A3 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
TN2012000377A1 (en) 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
WO2007071707A3 (en) Pneumococcal polysaccharide conjugate vaccine
MX2009013949A (en) Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates.
PH12015501269B1 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2007116028A3 (en) Conjugate vaccines
TH108545B (en) Mixture, multivalent, pneumococcal, polysaccharide-conjugate protein

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed